Business
Update on COVID-19 Test Development with Adeptrix
Update on COVID-19 Test Development with Adeptrix.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \n \n RNS Number : 3248P\n Avacta Group PLC\n 09 June 2020\n \n \n \n \n \n \n \n 9 June 2020\n \n \n Avacta Group plc\n \n \n (\"Avacta\" or \"the Group\" or \"the Company\")\n \n \n \n \n \n Update on COVID-19 Antigen Diagnostic Test Development with Adeptrix\n \n \n \n \n \n Highly specific prototype test detects the virus spike protein at clinically relevant concentrations \n \n \n \n \n \n Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased \n to announce that a BAMSTM diagnostic test for the COVID-19 infection, being developed with its partner Adeptrix (Beverly MA, USA), has reached prototype stage and can detect the coronavirus spike protein in model samples in the concentration range appropriate for a clinical diagnostic test. \n \n \n \n \n \n The bead-assisted mass spectrometry (\"BAMS\") assay uses the Affimer reagents specific to the SARS-COV-2 virus recently developed by Avacta to capture the virus spike protein from the sample for rapid detection by mass spectrometry.\n \n \n \n \n \n A prototype assay has now been developed and evaluated by Adeptrix using model samples containing the coronavirus spike protein. The unique method breaks up the spike protein captured from the samples by Affimer coated beads and is able to identify fragments of the spike protein using mass spectrometry, at concentrations in the range found in patient samples generated from standard throat swabs.\n \n \n \n \n \n The combination of the selectivity of the Affimer reagents used to capture the virus spike protein with the precision and accuracy of mass spectrometry detection provides for a very high degree of specificity in the assay. \n \n \n \n \n \n The next step in the development of the final product \n to run on the installed base of mass spectrometers in clinical laboratories around the world \n is to evaluate and optimise the BAMS assay using patient samples at laboratory sites in the UK and US which will be done imminently before moving to manufacturing, clinical validation to quantify the sensitivity and specificity and CE/FDA approval for professional use in the summer.\n \n \n \n \n \n Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:\n \n \n \"I am very pleased with the rapid progress made by o...